OR WAIT null SECS
March 16, 2023
Pfizer will acquire all outstanding shares of Seagen for a total of $43 billion.
27 drugs within Medicare will face penalties for having their prices raised faster than the rate of inflation.
March 15, 2023
The impact of the potential ban would have serious consequences for the availability of many drugs for European patients.
Organizations can better understand the maturity of AI-driven automation technology across their organization’s IT landscape through effective pharmacovigilance.
March 14, 2023
FDA has approved Acadia Pharmaceuticlas’ Daybue (trofinetide), the first treatment for Rett syndrome, a rare genetic disorder.
FDA has approved Pfizer’s ZAVZPRET (zavegepant), a new nasal spray treatment for migraine.
FDA is seeking $7.2 billion to enhance food safety and advance medical product availability.
Sumitovant Bipharma has completed its acquisition of Myovant Sciences for approximately $1.7 billion.
March 13, 2023
Silicon Valley Bank has collapsed, leaving many biotechnology companies unsure of the future.
March 10, 2023
Even after an FDA advisory panel voted 14–1 in October 2022 to remove the drug, Makena manufacturer Covis Pharma continued to press for some continued access to the therapy.